Adar Poonawalla, Serum Institute of India CEO (Dhiraj Singh/Bloomberg via Getty Images)

February 22, 2021 07:26 AM ESTUpdated 10:41 AM

Covid-19 roundup: Serum Institute chief asks countries to 'please be patient'; Sanofi and GlaxoSmithKline enter PhII with 'refined' vaccine formulation

Nicole DeFeudis

Editor

Serum Institute of India CEO Adar Poonawalla has asked countries waiting for doses of AstraZeneca and Oxford University’s vaccine to “please be patient,” as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Serum Institute chief asks countries to 'please be patient'; Sanofi and GlaxoSmithKline enter PhII with 'refined' vaccine formulation

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers

Covid-19 roundup: Serum In­sti­tute chief asks coun­tries to 'please be pa­tien­t'; Sanofi and Glax­o­SmithK­line en­ter PhII with 're­fined' vac­cine for­mu­la­tion

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Covid-19 roundup: Serum Institute chief asks countries to 'please be patient'; Sanofi and GlaxoSmithKline enter PhII with 'refined' vaccine formulation

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers